Since January 2020, the value of Moderna’s stock — which had embarked on a steady decline since its IPO — grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine.
Since the outset of the coronavirus disease 2019 (COVID-19) pandemic, the gut microbiome in COVID-19…
“Why are you choosing to not receive a COVID-19 vaccine?” This is a common question genuinely being asked by friends, family, and our physicians these days who genuinely care about our physical well-being, and we sincerely appreciate that concern.
